Antihypertensive therapy at the onset of an acute myocardial infarction predicts in-hospital mortality

Blood Pressure

Volumn 12, Issue 1, 2003, Pages 40-45

  Landmark, Knud ^a   Aursnes, Ivar ^a   Kvan, Elena ^a   Reikvam, Åsmund ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Acute myocardial infarction; Antihypertensive therapy; In hospital mortality

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLOPIDOGREL; DIGITALIS; DIGOXIN; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; NIFEDIPINE; NISOLDIPINE; NITRATE; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL; THIAZIDE DIURETIC AGENT; TICLOPIDINE; VERAPAMIL; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEATH; DEMOGRAPHY; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; FEMALE; HUMAN; HYPOKALEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL MODEL;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BENZOTHIADIAZINES; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG UTILIZATION; HOSPITAL MORTALITY; HUMANS; MALE; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NITRO COMPOUNDS; PATIENT ADMISSION; RECEPTORS, ANGIOTENSIN; RETROSPECTIVE STUDIES; SODIUM CHLORIDE SYMPORTER INHIBITORS; SURVIVAL RATE; TIME FACTORS; WARFARIN;

EID: 0037258014     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037050310003433     Document Type: Article

References (47)

1. Collins R, Peto R, Macmahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
2. Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Westeŕ P-O. Mobidity and mortality in the Swedish Trial in old patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5.
3. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-64.
4. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-12.
5. Hansson L, Hedner T, Lund-Johansen P, et al for the Nordil Study Group. Randomized trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-65.
6. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356: 366-72.
7. Lindholm LH, Hansson L, Ekbom T, et al for the STOP-Hypertension-2 Study Group. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetes patients: results from the Swedish Trial in Old Patients with Hypertension-2. J Hypertens 2000; 18: 1671-5.
8. Nidorf SM, Parsons RW, Thompson PL, Jamrozik KD, Hobbs MST. Reduced risk of death at 28 days in patients taking a β blocker before admission to hospital with myocardial infarction. Br Med J 1990; 300: 71-4.
9. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356: 1949-54.
10. Kizer JR, Kimmel SE. Epidemiologic review of the calcium channel blocker drugs. An up-to-date prospective on the proposed hazards. Arch Intern Med 2001; 161: 1145-58.
11. Kostis JB, Lacy CR, Cosgrove NM, Wilson AC. Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction. Am Heart J 1997; 133: 550-7.
12. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.
13. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.
14. Jespersen CM, Fischer Hansen J and the Danish Study Group on Verapamil in Myocardial infarction. Effect of verapamil on reinfarction and cardiovascular events in patients with arterial hypertension included in the Danish Verapamil Infarction Trial II. J Hum Hypertens 1994; 8: 85-8.
15. Rengo F, Carbonin P, Pahor M, De Caprio L CRIS Investigators. A controlled trial of verapamil in patients after acute myocardial infarction: results of the Calcium Antagonist Reinfarction Italian Study (CRIS). Am J Cardiol 1996; 77: 365-9.
16. Leitch JW, McElduff P, Dobson A, Heller R. Outcome with calcium channel antagonists after myocardial infarction: a community-based study. J Am Coll Cardiol 1998; 31: 111-17.
17. Bassett AL, Chakko S, Epstein M. Are calcium antagonists proarrhythmic?. J Hypertens 1997; 15: 915-23.
18. Zhang X, Fedida D. Potassium channel-blocking actions of nifedipine: a case for morbidity at high doses? Circulation 1998; 97: 2098-.
19. Lefrandt JD, Heitmann J, Sevre K, et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE Study. Am J Hypertens 2001; 14: 1083-9.
20. Rønning M, editor. Drug consumption in Norway, 1996-2000. WHO Collaborating Centre for Drug Statistics Methodology. Oslo, 2000.
21. Hollifield JW, Slaton PE. Thiazide diuretics, hypokalemia and cardiac arrhythmias. Acta Med Scand 1981; 647 Suppl: 67-73.
22. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1852-7.
23. Hoes AW, Grobbee DE, Lubsen J, Veld AJM in 't, Does E van der, Hofman A. Diuretics, β-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995; 123: 481-7.
24. Struthers AD, Whitesmith R, Reid JL. Prior thiazide diuretic treatment increases adrenaline-induced hypokalemia. Lancet 1983; 1: 1358-60.
25. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo Study. Am J Med 1980; 69: 725-32.
26. Holme I, Helgeland A, Hjermann I, Leren P, Lund-Larsen PG. Treatment of mild hypertension with diuretics. The importance of ECG abnormalities in the Oslo Study and in MRFIT. JAMA 1984; 251: 1298-9.
27. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999; 100: 1311-5.
28. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35: 1025-30.
29. Hock CE, Ribeiro LGT, Lefer AM. Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction. Am Heart J 1985; 109: 222-8.
30. 1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc Res 1998; 39: 401-12.
31. Raggi P, Dickson NR, Boyne M, et al. Influence of prior ACE inhibitor therapy on morbidity and mortality following acute myocardial infarction. Ann Pharmacother 1998; 32: 1141-6.
32. Landmark K, Aursnes I. Infarct size as assessed by peak enzyme levels is reduced in patients who are using angiotensin-converting enzyme inhibitors at the onset of infarction. Clin Drug Invest 2000; 20: 415-23.
33. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealy JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-104.
34. Liang C-S, Gavras H, Black J, Sherman LG, Hood WB. Renin-angiotensin system inhibition in acute myocardial infarction in dogs. Effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size. Circulation 1982; 66: 1249-55.
35. Hall AS, Tan LB, Ball SG. Inhibition of ACE/kinase-II, acute myocardial infarction, and survival. Cardiovasc Res 1994; 28: 190-8.
36. Greenwald L, Becker RC. Expanding the paradigm of the renin-angiotensin system and angiotensin-converting enzyme inhibition. Am Heart J 1994; 128: 997-1009.
37. Powell JS, Clozel J-P, Müller RKM, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-8.
38. Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induced smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991; 68: 450-6.
39. Dostal DE, Booz GW, Baker KM. Angiotensin II signalling partways in cardiac fibroblasts: conventional versus novel mechanisms in mediating cardiac growth and function. Mol Cell Biochem 1996; 157: 15-21.
40. Lande K, Os I, Kjeldsen SE, Westheim A, Hjermann I, Gjesdal K. Increased platelet size and release reaction in essential hypertension. J Hypertens 1987; 5: 401-6.
41. James IM, Dickenson EJ, Burgoyne E, et al. Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation. J Hum Hypertens 1988; 2: 21-5.
42. Wright RA, Flapan AD, Alberti KGMM, Ludlam CA, Fox KAA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73.
43. Baumgarten CR, Linz W, Kunkel G, Schölkens BA, Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol 1993; 108: 293-5.
44. Jaberansari MT, Baxter GF, Muller CA, et al. Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardium. J Am Col Cardiol 2001; 37: 1996-2001.
45. Mombouli J-V. ACE inhibition, endothelial function and coronary artery lesions - role of kinins and nitric oxide. Drugs 1997; 54 Suppl 5: 12-22.
46. Nakamura M, Funakoshi T, Yoshida H, Arakawa N, Suzuki T, Hiramori K. Endothelium-dependent vasodilation is augmented by angiotensin converting enzyme inhibition in healthy volunteers. J Cardiovas Pharmacol 1992; 20: 949-54.
47. Schlaifer JD, Wargovich TJ, O'Neill B, et al. on behalf of the TREND Investigators. Effect of quinapril on coronary blood flow in coronary artery disease with endothelial dysfunction. Am J Cardiol 1997; 80: 1596-7.